Roots Analysis Pvt. Ltd.

Size: px
Start display at page:

Download "Roots Analysis Pvt. Ltd."

Transcription

1 Roots Analysis Pvt. Ltd. -v3981/ Publisher Sample Phone: (US) or or (Int'l) Hours: Monday - Thursday: 5:30am - 6:30pm EST Fridays: 5:30am - 5:30pm EST MarketResearch.com

2 4.3. ANALYSIS OF THE DEVELOPMENT PIPELINE The ADC development pipeline is rich and dynamic. There are several molecules in the clinical and preclinical stage. As of January 2014, there are around 40 molecules in various phases of clinical development (I-III) and the pipeline is continuously expanding. Majority of the drugs are being developed for oncological indications including non-small-cell lung carcinoma (NSCLC), breast cancer, solid tumours etc. Tables enlist the ADCs in various stages of clinical development, mentioning the cytotoxic drug and conjugated antibody in each. Table 4.1 ADC Molecules in Clinical Development Roche / Genentech Drug Company Technology Provider Indication Phase of Development Kadcyla/ Trastuzumab-DM1 (mab anti-her2 linked to toxin DM1) Approved Pinatuzumab vedotin/rg7593 (mab anti-cd22 linked to toxin auristatin E) Roche/Genentech ImmunoGen Metastatic Breast Cancer Roche/Genentech Seattle Genetics Haematological Malignancies II Report Page 25 RG7450 (mab anti- STEAP1 linked to toxin auristatin E) RG7458 (mab anti- MUC16 linked to toxin auristatin E) Roche/Genentech Seattle Genetics Prostate Cancer I Roche/Genentech Seattle Genetics Ovarian Cancer I RG7596 (mab anti- CD79b linked to toxin auristatin E) Roche/Genentech Seattle Genetics Hematological Malignancies II RG7598 (auristatin) Roche/Genentech Seattle Genetics Multiple Myeloma I RG7599 (mab anti- NaPi2b linked to toxin auristatin) Roche/Genentech Seattle Genetics NSCLC, Ovarian Cancer I RG7600 (auristatin) Roche/Genentech Seattle Genetics Pancreatic, Ovarian Cancer I RG7636 (mab anti- ETBR linked to toxin auristatin) Roche/Genentech Seattle Genetics Melanoma I Continued on Pages Copyright 2014 Roots Analysis Private Limited Page 3

3 AURISTATINS ARE THE MOST COMMONLY USED CYTOTOXINS Table 10.2 and Figure 4.2 show the relative proportion of the number of marketed and clinical stage Report Page 40 molecules by type of toxin. Figure 4.2 ADCs in Clinical Development: Share (%) by Cytotoxin Used 2, 4.9% 1, 2.4% 2, 4.9% 11, 26.8% 5, 12.2% 20, 48.8% Auristatin Maytansine Calicheamicin PBD Topoisomerase SN 38 Others Source: Roots Analysis Auristatins are the most popular cytotoxins associated with ADCs. These synthetic antineoplastic agents are being extensively used by Seattle Genetics. Monomethyl auristatins (MMA) work by inhibition of cell division by blocking the polymerisation of tubulin. As they are highly toxic, their direct use can cause uncontrolled and unwanted cell death. MMA are used in two derivative forms, the uncharged MMAE and MMAF in which charged C-terminal phenylalanine residue attenuates its cytotoxic activity. Other toxins such as maytansinoid are also cytotoxic agents that inhibit assembly of microtubules. Maytansinoids are synthetic derivatives of maytansine, which can be isolated from plants of the genus Maytenus. The use of this toxin in ADC is being deployed by ImmunoGen and other licensees. Duocarmycin is an alternative payload under development in ADC molecules. Duocarmycins are DNA alkylating agents being explored by Bristol-Myers Squibb (BMS) / Medarex and Synthon. BMS has an ADC (MDX-1203 phase 1 clinical trials) comprising duocarmycin analogue linked to an antibody via a dipeptide linker. At the same time, Synthon currently has tested some ADCs using duocarmycin in preclinical studies, showing efficacy in low dose and safety in higher doses as well. Copyright 2014 Roots Analysis Private Limited Page 4

4 5.4. MAJORITY OF ADC CONTRACT MANUFACTURING IS CURRENTLY OUTSOURCED Figure 5.1 depicts our analysis of the in-house or contract manufacturing of various steps of ADC manufacturing for 12 marketed and clinical stage molecules. Wherever information wasn t readily available for confidentiality reasons, we have indicated our best guess based upon the research output. Furthermore, our interviews with several industry experts suggest that majority (70% 80%) of ADC manufacturing is indeed outsourced. Report Page 48 Figure 5.1 ADCs: Matrix View of Outsourced Activities by Company S.No. Drug Company Antibody Linker Cytotoxin Conjugation Fill/Finish 1 Adcetris Seattle Genetics / Millennium (Takeda) 2 Kadcyla Genentech 3 CMC 544 Pfizer/Wyeth? 4 CDX-011 Celldex Therapeutics 5 SAR 3419 Sanofi Aventis???? 6 BT-062 Biotest 7 PSMA ADC Progenics Pharmaceuticals 8 RG7593 Roche 9 RG7596 Roche 10 IMMU-130 Immunomedics? 11 IMMU-132 Immunomedics? 12 ABT-414 AbbVie Legend Outsourced Activity In-house Activity? Information not available Note: The Orange background indicates those cases where our research didn t confirm the status of respective activities (due to the confidential nature of the businesses); mapping in these cases represents the likely status based upon the partial information we were able to gather Source: Roots Analysis Specifically, for Adcetris, our research confirms that Seattle Genetics / Millennium outsource the various steps of ADC production to following CMOs: Copyright 2014 Roots Analysis Private Limited Page 5

5 5.5. PRESENCE OF CONTRACT MANUFACTURERS As indicated in Figure 5.1, majority of the companies, including the leading technology providers Seattle Genetics and ImmunoGen are dependent on contract manufacturers to supply the components. The presence of contract manufacturers is justified by the complexity of ADC manufacturing, which requires clean room facilities for working with antibodies and high containment facilities for small molecule cytotoxic drugs. Report Page 49 Table 5.1 lists some of the contract manufacturers for ADC components. We have discussed, in detail, the capabilities of these and other CMOs in subsequent sections of this report. Table 5.1 List of Contract Manufacturers and Their Capabilities in ADC Manufacturing Contract Manufacturers Antibody Production HPAPI 1 / Cytotoxic drugs Linkers Conjugation Fill/Finish Società Italiana Corticosteroidi S.r.l Albany Molecular Research, Inc. (AMRI) AbbVie (Abbott Contract Manufacturing) Boehringer Ingelheim Cytovance Biologics LLC Sigma Aldrich Fine Chemicals (SAFC) Baxter BioPharma Solutions Lonza Pierre Fabre Medicament Production Piramal Healthcare Pharma Solutions BSP Pharmaceuticals Novasep Carbogen Amcis Fujifilm Diosynth Biotechnologies Cambrex Corporation Goodwin Biotechnology Continued on the next Page 1 Highly Potent APIs Copyright 2014 Roots Analysis Private Limited Page 6

6 6.2 CYTOTOXIC FILL/FINISH: A GAP IN THE US There are limited number of contract manufacturers with capabilities for lyophilisation and fill/finish of cytotoxic drugs. These processes are required to be carried out within isolators for cytotoxic drugs such as ADCs. In 2011, one of the prominent contract manufacturers for cytotoxic injectable drugs, Ben Venue Laboratories, announced its plan to exit from the contract manufacturing business. The company was one of the few CMOs in the US with fill/finish capacity for cytotoxic drugs. Ben Venue Laboratories did the lyophilisation and filling for Pfizer s ADC Report Page 60 Mylotarg, which was later withdrawn from the US market. 2 The company planned to exit from its contract manufacturing business due to the huge investment that was required for conforming its manufacturing facility to the FDA standards. The exit of Ben Venue has created opportunity for other CMOs in the market. However, our research reveals that there are still only very few CMOs in the US with capabilities for fill/finish of cytotoxic drugs. Figure 6.4 highlights the location of fill / finish facilities of various CMOs. Figure 6.4 ADC Fill / Finish: Worldwide CMO Facilities Source: Roots Analysis Similar analysis available for HPAPI and Conjugation facilities on Pages Source: Copyright 2014 Roots Analysis Private Limited Page 7

Cancer, Autoimmune & Other Serious Diseases

Cancer, Autoimmune & Other Serious Diseases Focused on Therapy: Cancer, Autoimmune & Other Serious Diseases World ADC San Francisco 2013 Cynthia L. Sullivan, President & CEO It s all about Life Good morning. Thank you for attending this session.

More information

Regulatory perspective for successful antibody-drug conjugate development

Regulatory perspective for successful antibody-drug conjugate development Regulatory perspective for successful antibody-drug conjugate development Wen Jin Wu, M.D., Ph.D. Senior Investigator Division of Biotechnology Review and Research I Office of Biotechnology Products (OBP)

More information

ADCs in Clinical Trials: What Does the Global Landscape Look Like? James Eslea MacDonald Hanson Wade

ADCs in Clinical Trials: What Does the Global Landscape Look Like? James Eslea MacDonald Hanson Wade ADCs in Clinical Trials: What Does the Global Landscape Look Like? James Eslea MacDonald Hanson Wade Welcome Today I d like to talk about some work we ve been doing recently to carry out some metaanalysis

More information

Redefining cancer therapy 2012 ANNUAL REPORT

Redefining cancer therapy 2012 ANNUAL REPORT Redefining cancer therapy 2012 ANNUAL REPORT Putting patients first KAITLYNNE (pictured on cover), age 20, was diagnosed with Hodgkin lymphoma when she was a sophomore in high school. Despite receiving

More information

IMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases

IMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases February 2016 Forward-Looking Statements This presentation, in addition to historical information, contains certain

More information

How to develop Antibody Drug Conjugates: Bioanalysis Contribution

How to develop Antibody Drug Conjugates: Bioanalysis Contribution How to develop Antibody Drug Conjugates: Bioanalysis Contribution Recommendations and survey results Presenter: Matt Barfield on behalf of the EBF TT43 7th Open Symposium 19 th November 2014 Barcelona

More information

Cellectar Biosciences

Cellectar Biosciences Cellectar Biosciences NASDAQ: CLRB September 2015 1 Safe Harbor Statement This slide presentation contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation

More information

PlantForm Corporation

PlantForm Corporation PlantForm Corporation Professor J. Christopher Hall CSO PlantForm Corporation Canada s Top10 Winner Life Sciences 2008/9 Innovator of the Year Guelph, Canada, 2010 Opportunity The introduction of more

More information

Cellectar Biosciences

Cellectar Biosciences Cellectar Biosciences NASDAQ: CLRB October 2015 1 Safe Harbor Statement This slide presentation contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation

More information

Antibody drug conjugates

Antibody drug conjugates THOMAS ROHRER Antibody drug conjugates Potent weapons for the oncology arsenal Thomas Rohrer ABSTRACT Antibody Drug Conjugates (ADCs) are monoclonal antibodies attached to biologically active drugs by

More information

CHAPTER FOUR: CLINICAL TRIAL COST AND FUNDING... 30

CHAPTER FOUR: CLINICAL TRIAL COST AND FUNDING... 30 CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 INTENDED AUDIENCE... 2 METHODOLOGY... 2 ANALYST CREDENTIALS... 2 SCOPE OF REPORT... 2 INFORMATION SOURCES...

More information

Cancer Monoclonal Antibodies Market Forecast to 2017

Cancer Monoclonal Antibodies Market Forecast to 2017 RNCOS Page 1 Table of Contents 1. Analyst View 2. Research Methodology 3. The Global Burden of Cancer 3.1 Cancer - A Leading Cause of Death 3.2 Current and Future Cancer Cases: By Type and Geography 3.3

More information

The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies

The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies Greetings from Chicago! Beaches Yes! Pharma Beginnings! Bogota 1974 Selling Drugs in Colombia Global

More information

Syndax Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update Following IPO

Syndax Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update Following IPO Syndax Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update Following IPO ENCORE 601 Phase 1b dose escalation has been completed and safety confirmation has commenced

More information

Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019

Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 Brochure More information from http://www.researchandmarkets.com/reports/3453273/ Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 Description: About non-small cell lung cancer therapeutics

More information

ADCs: A Targeted Approach for the Treatment of Cancer

ADCs: A Targeted Approach for the Treatment of Cancer ADCs: A Targeted Approach for the Treatment of Cancer Update of ADC in development at Sanofi 6th world ADC San Diego 2015 October 19th-22nd Cécile Combeau, Early Development Oncology, Sanofi 1 Drug Dose

More information

New Advances in Cancer Treatments. March 2015

New Advances in Cancer Treatments. March 2015 New Advances in Cancer Treatments March 2015 Safe Harbour Statement This presentation document contains certain forward-looking statements and information (collectively, forward-looking statements ) within

More information

Biopharmaceutical Perspectives of Outsourcing: what are supply chain management issues and opportunities

Biopharmaceutical Perspectives of Outsourcing: what are supply chain management issues and opportunities 1 Biopharmaceutical Perspectives of Outsourcing: what are supply chain management issues and opportunities Presented by Dr. Philipp Hess Supply Chain Management Issues and Opportunities 2 1. How do we

More information

ASMS Regulated Bioanalysis Interest Group (RBIG) Workshop. Antibody-Drug Conjugates (ADC) A Complex Problem in Regulated Bioanalysis.

ASMS Regulated Bioanalysis Interest Group (RBIG) Workshop. Antibody-Drug Conjugates (ADC) A Complex Problem in Regulated Bioanalysis. ASMS Regulated Bioanalysis Interest Group (RBIG) Workshop Antibody-Drug Conjugates (ADC) A Complex Problem in Regulated Bioanalysis June 17, 2014 Presiding: Dr. Keyang Xu (Genentech) and Dr. Fabio Garofolo

More information

Global Monoclonal Antibodies Pipeline Insight 2015

Global Monoclonal Antibodies Pipeline Insight 2015 Brochure More information from http://www.researchandmarkets.com/reports/3113388/ Global Monoclonal Antibodies Pipeline Insight 2015 Description: Ever since the Nobel Prize was bestowed on the person who

More information

OPEN Regional Meeting June 26 and June 27, 2015 Hyatt Regency Pier Sixty Six 2301 Southeast 17th Street Fort Lauderdale, Florida, 33316 AGENDA

OPEN Regional Meeting June 26 and June 27, 2015 Hyatt Regency Pier Sixty Six 2301 Southeast 17th Street Fort Lauderdale, Florida, 33316 AGENDA OPEN Regional Meeting June 26 and June 27, 2015 Hyatt Regency Pier Sixty Six 2301 Southeast 17th Street Fort Lauderdale, Florida, 33316 Friday, June 26 AGENDA 10:00 am - 10:45 am Registration; Breakfast

More information

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions

More information

Company Presentation June 2011 Biotest AG 0

Company Presentation June 2011 Biotest AG 0 Company Presentation June 2011 0 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of and

More information

Current affiliation: UCB Pharma Ltd.; Slough, UK

Current affiliation: UCB Pharma Ltd.; Slough, UK Meeting Report mabs 5:1, 5 12; January/February 2013; 2013 Landes Bioscience Meeting Report American Association of Pharmaceutical Scientists National Biotechnology Conference Short Course: Translational

More information

Excellence in Oncology Clinical Trials

Excellence in Oncology Clinical Trials Oncology Clinical Trials We work to find a better way. We work to raise standards and deliver more. We break new ground to make progress possible. Oncology Research ICON is a global provider of outsourced

More information

Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference

Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference Two New Clinical Programs and Significant Expansion of Cancer Pipeline Planned for 2004 SOUTH SAN FRANCISCO, Calif., Jan. 13 /PRNewswire-FirstCall/

More information

A Letter from MabVax Therapeutics President and Chief Executive Officer

A Letter from MabVax Therapeutics President and Chief Executive Officer A Letter from MabVax Therapeutics President and Chief Executive Officer Dear Fellow Stockholder: You have invested in MabVax Therapeutics because you share our passion for finding new therapies for the

More information

Groundbreaking Collaborative Clinical Trial Launched

Groundbreaking Collaborative Clinical Trial Launched Groundbreaking Collaborative Clinical Trial Launched For immediate release Media Contacts: June 16, 2014 Richard Folkers Alison Hendrie 9:00 a.m., EDT Foundation for the NIH Rubenstein Communications (301)

More information

Towards Well-Defined ADCs (Antibody Drug Conjugates)

Towards Well-Defined ADCs (Antibody Drug Conjugates) Towards Well-Defined ADCs (Antibody Drug Conjugates) Next generation approach June 10, 2015 Dr. Yong Zu Kim, CEO and President LegoChem Biosciences, Inc. Antibody Drug Conjugates ADC binds to Antigen Endocytosis

More information

New Global Trends in Novel

New Global Trends in Novel New Global Trends in Novel Oncology Drug Development Harish Dave, MD, MBA Vice President Medical and Scientific Services Quintiles September 18, 2010 Oncology Market Attractiveness Opportunity exists in

More information

Commercial Insight: Cytotoxic Therapies Market Growth Will Slow Due To Increasing Genericization

Commercial Insight: Cytotoxic Therapies Market Growth Will Slow Due To Increasing Genericization Commercial Insight: Cytotoxic Therapies Market Growth Will Slow Due To Increasing Genericization Report summary In-depth analysis of the current and future cytotoxic therapies market across the US, 5EU

More information

Curriculum Vitae of Luca Gianni

Curriculum Vitae of Luca Gianni Education: 1976: State University of Milan, Milan, Italy: Medical Doctor with honors 1981: State University of Milan, Milan, Italy: Board- Certified in Internal Medicine Brief Chronology of Activities

More information

Antibody-drug conjugates as novel anti-cancer chemotherapeutics

Antibody-drug conjugates as novel anti-cancer chemotherapeutics Antibody-drug conjugates as novel anti-cancer chemotherapeutics Christina Peters* and Stuart Brown# *#School of Life Sciences, Nottingham Medical School, Queen s Medical Centre, Nottingham, UK, NG7 2UH

More information

IMMUNOMEDICS, 300 The American Road, Morris Plains, New Jersey 07950 (973) 605-8200 Fax (973) 605-8282

IMMUNOMEDICS, 300 The American Road, Morris Plains, New Jersey 07950 (973) 605-8200 Fax (973) 605-8282 IMMUNOMEDICS, INC. 300 The American Road, Morris Plains, New Jersey 07950 (973) 605-8200 Fax (973) 605-8282 IMMUNOMEDICS ANNOUNCES FIRST QUARTER FISCAL 2014 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS Morris

More information

Médecine de précision médecine personnalisée en Oncologie. Fabien Calvo, Directeur Recherche et Innovation, INCa, Directeur ITMO Cancer, AVIESAN

Médecine de précision médecine personnalisée en Oncologie. Fabien Calvo, Directeur Recherche et Innovation, INCa, Directeur ITMO Cancer, AVIESAN Médecine de précision médecine personnalisée en Oncologie Fabien Calvo, Directeur Recherche et Innovation, INCa, Directeur ITMO Cancer, AVIESAN Successful targeted drug development Rapid identification

More information

GUIDANCE ON THE SAFE HANDLING OF MONOCLONAL ANTIBODY (mab) PRODUCTS

GUIDANCE ON THE SAFE HANDLING OF MONOCLONAL ANTIBODY (mab) PRODUCTS GUIDANCE ON THE SAFE HANDLING OF MONOCLONAL ANTIBODY (mab) PRODUCTS 5 th Edition November 2015 NHS Pharmaceutical Quality Assurance Committee 2015 British Oncology Pharmacists Association Pharmaceutical

More information

Acquisition of Boston Biomedical Inc. February 29, 2012 Dainippon Sumitomo Pharma Co., Ltd.

Acquisition of Boston Biomedical Inc. February 29, 2012 Dainippon Sumitomo Pharma Co., Ltd. Acquisition of Boston Biomedical Inc. February 29, 2012 Dainippon Sumitomo Pharma Co., Ltd. Oncology Strategy and Acquisition Significance 1 Commitment to Oncology Entering the Oncology Area Globally External

More information

EFPIA Position Paper on REACH. Executive Summary. Position Paper. Draft Final. Author: EFPIA Date: October 2015 Version: Final

EFPIA Position Paper on REACH. Executive Summary. Position Paper. Draft Final. Author: EFPIA Date: October 2015 Version: Final Draft Final EFPIA Position Paper on REACH Author: EFPIA Date: October 2015 Version: Final Position Paper Executive Summary An increasing number of substances used in the pharmaceutical manufacturing process

More information

May 2008 Volume: TMRCTH CANCER THERAPEUTICS MARKETS (SAMPLE COPY, NOT FOR RESALE)

May 2008 Volume: TMRCTH CANCER THERAPEUTICS MARKETS (SAMPLE COPY, NOT FOR RESALE) TriMark Publications May 2008 Volume: TMRCTH08-0501 CANCER THERAPEUTICS MARKETS (SAMPLE COPY, NOT FOR RESALE) Trends, Industry Participants, Product Overviews and Market Drivers TABLE OF CONTENTS 1. Overview

More information

Small-Cell Lung Cancer Global Clinical Trials Review, H2, 2015

Small-Cell Lung Cancer Global Clinical Trials Review, H2, 2015 Brochure More information from http://www.researchandmarkets.com/reports/3398017/ Small-Cell Lung Cancer Global Clinical Trials Review, H2, 2015 Description: Small-Cell Lung Cancer Global Clinical Trials

More information

17th - 20th February 2014 Frankfurt, Germany

17th - 20th February 2014 Frankfurt, Germany Yet another grand slam of a conference. 17th - 20th February 2014 Frankfurt, Germany Select your lead candidate with confidence Improve preclinical predictability Maximise clinical efficacy Our Partners:

More information

Rx-360 An International Pharmaceutical Supply Chain Consortium

Rx-360 An International Pharmaceutical Supply Chain Consortium Rx-360 An International Pharmaceutical Supply Chain Consortium Overview Rx-360 and the Audit Sharing Program September 2011 Rx-360 Members (Continuously updated list at www.rx-360.org) Manufacturers (24)

More information

Highly Potent APIs The right platform, people and procedures for successful development and manufacturing

Highly Potent APIs The right platform, people and procedures for successful development and manufacturing Pharma&Biotech Highly Potent APIs The right platform, people and procedures for successful development and manufacturing Custom Manufacturing and Development Services for Highly Potent APIs Pharma&Biotech

More information

Bispecific Antibody Therapeutics Market (2nd Edition), 2014-2024

Bispecific Antibody Therapeutics Market (2nd Edition), 2014-2024 Brochure More information from http://www.researchandmarkets.com/reports/3047307/ Bispecific Antibody Therapeutics Market (2nd Edition), 2014-2024 Description: The concept of bispecific antibodies is increasingly

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Ado-Trastuzumab Emtansine (Trastuzumab-DM1) for Treatment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ado_trastuzumab_emtansine_(trastuzumab-dm1)_for_treatment_of_her-2_positivemalignancies

More information

10 th EADO Congress Vilnius, 7-10 May 2014. Ipilimumab update. Michele Maio

10 th EADO Congress Vilnius, 7-10 May 2014. Ipilimumab update. Michele Maio 10 th EADO Congress Vilnius, 7-10 May 2014 Ipilimumab update Michele Maio Medical Oncology and Immunotherapy, Department of Oncology University Hospital of Siena, Istituto Toscano Tumori SIENA, ITALY Evolving

More information

Read the Questions Carefully

Read the Questions Carefully PHT. 463- (Quality Control of Pharmaceutical Dosage Forms) Midterm Exam I Dr. Ibrahim A. Alsarra s Section Part I Read the Questions Carefully TRUE OR FALSE: Indicate whether the statement is true or false

More information

Creating a cgmp Facility for Early Clinical Trials of Molecular Imaging and Therapeutic Agents

Creating a cgmp Facility for Early Clinical Trials of Molecular Imaging and Therapeutic Agents Designing for the Frontiers of Research Creating a cgmp Facility for Early Clinical Trials of Molecular Imaging and Therapeutic Agents Richard J. Mohr What if it were possible to treat a cancer patient

More information

Business Development & Licensing Journal For the Pharmaceutical Licensing Groups

Business Development & Licensing Journal For the Pharmaceutical Licensing Groups Issue 12 June 21 www.plg-uk.com Business Development & Licensing Journal For the Pharmaceutical Licensing Groups Follow-on biologics Co-marketing: a successful model Trends in dealmaking Finding new products

More information

The Ultimate Healthcare & Biotechnology Event in 2010. Deborah Rathjen CEO & Managing Director 24 March 2010

The Ultimate Healthcare & Biotechnology Event in 2010. Deborah Rathjen CEO & Managing Director 24 March 2010 The Ultimate Healthcare & Biotechnology Event in 2010 Deborah Rathjen CEO & Managing Director 24 March 2010 Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking"

More information

Companion Diagnostics in Pharmaceutical Development. Robert C Newton, Ph.D. VP, Drug Discovery Biology Incyte Corporation

Companion Diagnostics in Pharmaceutical Development. Robert C Newton, Ph.D. VP, Drug Discovery Biology Incyte Corporation Companion Diagnostics in Pharmaceutical Development Robert C Newton, Ph.D. VP, Drug Discovery Biology Incyte Corporation Why the Interest in Companion Diagnostics? Personalized Medicine using diagnostics

More information

Cellectar Biosciences

Cellectar Biosciences Cellectar Biosciences NASDAQ: CLRB January 11, 2016 1 Safe Harbor Statement This slide presentation contains forward-looking statements. Such statements are valid only as of today, and we disclaim any

More information

BioWorld s PARTNER in FOCUS: Covance AN ADVERTISING SERVICE FROM BIOWORLD

BioWorld s PARTNER in FOCUS: Covance AN ADVERTISING SERVICE FROM BIOWORLD BioWorld s PARTNER in FOCUS: Covance AN ADVERTISING SERVICE FROM BIOWORLD PARTNERING Trend Allows Smart CROs TO Provide Gamut of Services TO Any Size COMPANy Five years ago, contract research organizations

More information

Pfizer Forms Global Alliance with Merck KGaA, Darmstadt, Germany to Accelerate Presence in Immuno-Oncology. November 17, 2014

Pfizer Forms Global Alliance with Merck KGaA, Darmstadt, Germany to Accelerate Presence in Immuno-Oncology. November 17, 2014 Pfizer Forms Global Alliance with Merck KGaA, Darmstadt, Germany to Accelerate Presence in Immuno-Oncology November 17, 2014 Forward-looking statements Our discussions during this conference call will

More information

BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED

BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED ASX ANNOUNCEMENT 3 August 2011 ABN 53 075 582 740 BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED Data from renal cancer trial supports progression of the trial: o Combination

More information

NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds

NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.

More information

An integrated global healthcare company

An integrated global healthcare company An integrated global healthcare company 1 A Mission to create healthier communities globally Zydus Cadila is dedicated to life In all its dimensions. Our world is shaped by a passion for innovation, commitment

More information

Bolus Injectors Market

Bolus Injectors Market Sample Pages Bolus Injectors Market 2014-2024 Copyright 2012 Banyan Wharf Consultants Ltd. Page 1 This page is intentionally left blank Copyright 2013 Roots Analysis Private Ltd. All rights reserved. No

More information

CMC Sourcing in Transition: Consolidation, Offshoring and the Market Outlook. Pharmaceutical Technology Breakfast at AAPS November 7, 2005

CMC Sourcing in Transition: Consolidation, Offshoring and the Market Outlook. Pharmaceutical Technology Breakfast at AAPS November 7, 2005 CMC Sourcing in Transition: Consolidation, Offshoring and the Market Outlook Pharmaceutical Technology Breakfast at AAPS Market conditions CRO/CMO posted strong results in H1 2005 H1 2005 Revenue Growth

More information

ENDORSED BY THE GOVERNANCE COMMITTEE

ENDORSED BY THE GOVERNANCE COMMITTEE Guideline for the Preparation or Manipulation of Monoclonal Antibodies (MABs) and related compounds such as Fusion Proteins, used in the Treatment of Cancer Date Approved by Network Governance July 2012

More information

drugs in development CuraScript Specialty Pharmacy Management Guide & Trend Report

drugs in development CuraScript Specialty Pharmacy Management Guide & Trend Report CuraScript Specialty Pharmacy Management Guide & Trend Report Drugs in Development There are currently more than 324 drugs in development for nearly 150 disease states. These potential new medications

More information

J.P. MORGAN HEALTHCARE CONFERENCE

J.P. MORGAN HEALTHCARE CONFERENCE J.P. MORGAN HEALTHCARE CONFERENCE Bill Chase, Executive Vice President, Finance and CFO January 14, 2015 Disclaimer and Forward Looking Statement This presentation and its contents are confidential and

More information

12. November 2013 Jan Endell. From library to bedside: Potential of the anti-cd38 antibody MOR202 in combination therapy of multiple myeloma

12. November 2013 Jan Endell. From library to bedside: Potential of the anti-cd38 antibody MOR202 in combination therapy of multiple myeloma 12. November 2013 Jan Endell From library to bedside: Potential of the anti-cd38 antibody MOR202 in combination therapy of multiple myeloma The MorphoSys Pipeline 21 Clinical Programs, 82 Total Program

More information

Immunovaccine Inc. (TSX-V: IMV)

Immunovaccine Inc. (TSX-V: IMV) May 2014 Immunovaccine Inc. (TSX-V: IMV) Targeted T cell Activation Immunotherapies FORWARD-LOOKING STATEMENTS This document contains forward-looking information pursuant to applicable securities law.

More information

Critical Path Institute

Critical Path Institute Critical Path Institute Accelerating drug development for Alzheimer s Disease through regulatory science Martha A. Brumfield, PhD President and CEO Accelerating the Path to a Healthier World 1 Critical

More information

ALK+ lung cancer and the Blood-Brain Barrier (BBB) A concise guide

ALK+ lung cancer and the Blood-Brain Barrier (BBB) A concise guide ALK+ lung cancer and the Blood-Brain Barrier (BBB) A concise guide Contents Section Page number Section 1: Lung cancer and ALK+ NSCLC 3 Section 2: The Blood-Brain Barrier (BBB): What and why? 4 Section

More information

Cytotoxic and Biotherapies Credentialing Programme Module 2

Cytotoxic and Biotherapies Credentialing Programme Module 2 Cytotoxic and Biotherapies Credentialing Programme Module 2 1. The Cell Cycle 2. Cancer Therapies 3. Adjunctive Therapies On completion of this module the RN will State the difference between a normal

More information

Presented at: Jefferies 2015 Global Healthcare Conference

Presented at: Jefferies 2015 Global Healthcare Conference Presented at: Jefferies 2015 Global Healthcare Conference Agenda 1 Overview & Service Platforms 2 Adaptability, Scalability & Expansion Plans 3 Best Practices 4 Blue Chip Customer Base 5 Roadmap of Evolution

More information

6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality

6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality 6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality March 24-25, 2015 Wyndham Philadelphia Historic District, Philadelphia, PA www.exlevents.com/gcp Sponsors

More information

Chugai Pharmaceutical Co., Ltd. Oncology Area, Scientific Group 2, Breast Cancer Group Takehiro Yamaguchi, Herceptin Product Manager

Chugai Pharmaceutical Co., Ltd. Oncology Area, Scientific Group 2, Breast Cancer Group Takehiro Yamaguchi, Herceptin Product Manager Anti-malignant Tumor Agent with Anti-HER2 Humanized Monoclonal Antibody: Biologics, Designated drug, Prescription drug HERCEPTIN Injection 60 HERCEPTIN Injection 150 Trastuzumab (genetical recombination)

More information

Biologics: Specific Drug Safety Challenges. Violetta B. Kyburz

Biologics: Specific Drug Safety Challenges. Violetta B. Kyburz Biologics: Specific Drug Safety Challenges Violetta B. Kyburz 2012 2013 2014 Biologics: Specific Drug Safety Challenges Topics for discussion Particular issues in the preclinical development of biologics

More information

CHEM-E4140 Selectivity 12. Pharma Business

CHEM-E4140 Selectivity 12. Pharma Business CHEM-E4140 Selectivity 12. Pharma Business Prof. Ari Koskinen Laboratory of Organic Chemistry C318 Pharma Business Total volume ca 1100 G$ (Shell 421G$; Walmart 486G$; Toyota 252 G$). Annually approx 25

More information

Custom Antibodies & Recombinant Proteins

Custom Antibodies & Recombinant Proteins Custom Antibodies & Recombinant Proteins INTRODUCTION Custom services to meet your research and development requirements Improvements in health, medicine and diagnostics over the past century can be largely

More information

Aposense Enhancing Drug Effects

Aposense Enhancing Drug Effects Aposense Enhancing Drug Effects Miri Ben-Ami, M.D. CEO IATI Biomed June 2013 Aposense Proprietary FORWARD LOOKING STATEMENTS The following slides contain forward-looking statements that include, but are

More information

Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies

Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies Fern Barkalow, Ph.D, Senior Analyst, Oncology Citeline One of the biggest challenges facing biosimilar drug developers is

More information

Biologic Basis of Breast Cancer Treatment

Biologic Basis of Breast Cancer Treatment Biologic Basis of Breast Cancer Treatment Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington School

More information

The Future of Monoclonal Antibodies Therapeutics: Innovation in Antibody Engineering, Key Growth Strategies and Forecasts to 2011

The Future of Monoclonal Antibodies Therapeutics: Innovation in Antibody Engineering, Key Growth Strategies and Forecasts to 2011 Brochure More information from http://www.researchandmarkets.com/reports/344881/ The Future of Monoclonal Antibodies Therapeutics: Innovation in Antibody Engineering, Key Growth Strategies and Forecasts

More information

CUSTOM ANTIBODIES & RECOMBINANT PROTEINS

CUSTOM ANTIBODIES & RECOMBINANT PROTEINS CUSTOM ANTIBODIES & RECOMBINANT PROTEINS INTRODUCTION Custom services to meet your research and development requirements Improvements in health, medicine and diagnostics over the past century can be largely

More information

Trends in the pharmaceutical industry and potential impact on future innovation and access to medicines

Trends in the pharmaceutical industry and potential impact on future innovation and access to medicines Trends in the pharmaceutical industry and potential impact on future innovation and access to medicines The R&D Process: Long, Complex, and Costly Average cost of R&D is $1.2 Billion The Current Challenge

More information

Biotest AG. Company Presentation. July 2013. Company Presentation EU. Biotest AG

Biotest AG. Company Presentation. July 2013. Company Presentation EU. Biotest AG Company Presentation July 2013 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of and its

More information

Targeted Chemotherapy: Guiding patients to more personalized care

Targeted Chemotherapy: Guiding patients to more personalized care Targeted Chemotherapy: Guiding patients to more personalized care Anna Hitron, Pharm.D, MS, MBA, BCOP Oncology Pharmacy Specialist Baptist Health Louisville September 10, 2015 Objectives Discuss the role

More information

TRENDS SHAPING THE FUTURE OF PERSONALIZED CARE AND THE DELIVERY OF SPECIALTY PHARMACY

TRENDS SHAPING THE FUTURE OF PERSONALIZED CARE AND THE DELIVERY OF SPECIALTY PHARMACY TRENDS SHAPING THE FUTURE OF PERSONALIZED CARE AND THE DELIVERY OF SPECIALTY PHARMACY Key Takeaways from the June 18, 2013 Regional Symposium Nashville, Tennessee THE SYMPOSIUM Trends Shaping the Future

More information

FDA grants Roche s cancer immunotherapy Tecentriq (atezolizumab) accelerated approval for people with a specific type of advanced bladder cancer

FDA grants Roche s cancer immunotherapy Tecentriq (atezolizumab) accelerated approval for people with a specific type of advanced bladder cancer Media Release Basel, 19 May 2016 FDA grants Roche s cancer immunotherapy Tecentriq (atezolizumab) accelerated approval for people with a specific type of advanced bladder cancer First and only anti-pd-l1

More information

Europe Pradaxa Market Report 2016

Europe Pradaxa Market Report 2016 Report Information More information from: https://www.wiseguyreports.com/reports/650908 Europe Pradaxa Market Report 2016 Report / Search Code: WGR650908 Publish Date: 22 September, 2016 Price 1-user PDF

More information

LOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT

LOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT LOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT Puma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of

More information

ASCO 12. PD-1 Immunotherapy Makes a Splash at ASCO

ASCO 12. PD-1 Immunotherapy Makes a Splash at ASCO PD-1 Immunotherapy Makes a Splash at ASCO By Gregory R. Wolfe, PhD Epigenetic variation and genetic instability in tumor cells yield a variety of tumor antigens that the immune system can recognize to

More information

Implement A Holistic Approach To Justification Building The Business Case

Implement A Holistic Approach To Justification Building The Business Case Implement A Holistic Approach To Justification Building The Business Case Hairong (Angela) Zhou Sr. Sourcing Manager SMPS Sourcing Genentech July 15 th, 2015 Outline 2 Effectively breakdown organizational

More information

Monoclonal Antibodies in The Treatment of Multiple Myeloma

Monoclonal Antibodies in The Treatment of Multiple Myeloma Monoclonal Antibodies in The Treatment of Multiple Myeloma Sundar Jagannath, MD Professor of Medicine Mt. Sinai School of Medicine New York, NY The Tisch Cancer Institute Disclosure 2 Honorarium: Celgene

More information

Attached from the following page is the press release made by BMS for your information.

Attached from the following page is the press release made by BMS for your information. November 19, 2014 Study Comparing Opdivo (nivolumab) to Chemotherapy in Treatment Naïve Advanced Melanoma Patients Marks First PD-1 Immune Checkpoint Inhibitor to Demonstrate a Survival Benefit in a Phase

More information

DESIGN & ENDPOINT OF PHASE I / TRANSLATIONAL RESEARCH MONDAY 7 TH JULY 2014 UZMA RAYANI CLINICAL OPERATIONS MANAGER

DESIGN & ENDPOINT OF PHASE I / TRANSLATIONAL RESEARCH MONDAY 7 TH JULY 2014 UZMA RAYANI CLINICAL OPERATIONS MANAGER DESIGN & ENDPOINT OF PHASE I / TRANSLATIONAL RESEARCH MONDAY 7 TH JULY 2014 UZMA RAYANI CLINICAL OPERATIONS MANAGER Drug Development Office 100 DRUG DEVELOPMENT AND OPERATIONAL STAFF NEW AGENTS IN CLINICAL

More information

Outline. Predictive Assays in Radiation Therapy Immunotherapy in Cancer Treatment. Introduction. Current clinical practice

Outline. Predictive Assays in Radiation Therapy Immunotherapy in Cancer Treatment. Introduction. Current clinical practice Predictive Assays in Radiation Therapy Immunotherapy in Cancer Treatment Radiation Biology Outline Introduction: Predictive assays in radiation therapy Examples for specific tumors Immunotherapy Summary

More information

Biotherapeutic Medicines

Biotherapeutic Medicines International Federation of Pharmaceutical Manufacturers & Associations Biotherapeutic Medicines Grasping the New Generation of Treatments Biotherapeutic medicines are an integral and valuable part of

More information

Current Approaches for ADME Characterization of Antibody-Drug Conjugates

Current Approaches for ADME Characterization of Antibody-Drug Conjugates 2016 IQ Webinar Series Presents: Current Approaches for ADME Characterization of Antibody-Drug Conjugates Sponsored by the IQ Drug Metabolism Leadership Group 1 Current Approaches for ADME Characterization

More information

Pennino Corporation TECHNOLOGY TO IMPROVE LIFE

Pennino Corporation TECHNOLOGY TO IMPROVE LIFE Pennino Corporation TECHNOLOGY TO IMPROVE LIFE Agenda The Opportunity Highlights Corporate Profile NYU Relationship Obesity and Diabetes Graphics and Facts Next Stage of Development Efficacy and Safety

More information

MAB Solut. MABSolys Génopole Campus 1 5 rue Henri Desbruères 91030 Evry Cedex. www.mabsolut.com. is involved at each stage of your project

MAB Solut. MABSolys Génopole Campus 1 5 rue Henri Desbruères 91030 Evry Cedex. www.mabsolut.com. is involved at each stage of your project Mabsolus-2015-UK:Mise en page 1 03/07/15 14:13 Page1 Services provider Department of MABSolys from conception to validation MAB Solut is involved at each stage of your project Creation of antibodies Production

More information

The New Kid on the Block for Advanced Renal Cell Carcinoma

The New Kid on the Block for Advanced Renal Cell Carcinoma The New Kid on the Block for Advanced Renal Cell Carcinoma Wyeth Pharmaceuticals recently launched Torisel (temsirolimus), a targeted, first-in-class mtor inhibitor. This new treatment for metastatic renal

More information

US Investor Presentation May 2010

US Investor Presentation May 2010 US Investor Presentation May 2010 Important Notice The purpose of the presentation is to provide an update of the business of Prima Biomed Ltd ACN 009 237 889 (ASX:PRR) (Prima). These slides have been

More information

9. WestLB Deutschland Conference. Frankfurt November 16, 2011

9. WestLB Deutschland Conference. Frankfurt November 16, 2011 9. WestLB Deutschland Conference Frankfurt November 16, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking

More information

Achievements Report CURING CANCER. Of all the questions addressed to CPRIT, the toughest is: When are you going to find a cure for

Achievements Report CURING CANCER. Of all the questions addressed to CPRIT, the toughest is: When are you going to find a cure for Achievements Report August 2015 CURING CANCER Of all the questions addressed to CPRIT, the toughest is: When are you going to find a cure for cancer? Since cancer is complex and comes in many forms, its

More information

As featured in. Orphan disease specialists find home with Big Pharma.

As featured in. Orphan disease specialists find home with Big Pharma. Orphan disease specialists find home with Big Pharma. By Maura Musciacco Senior Analyst January 2013 Tumbling over the patent cliff, many big pharma companies are being forced to find new strategies for

More information